Evaluate’s Orphan Drug Report 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights […]
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights […]
Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in […]
Shots: In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo […]
Shots: The company to initiate the clinical trial assessing the safety and efficacy of its COVID-19 drug based on the Grifols’ immunoglobulin Gamunex-C and containing […]
Shots: The companies plan to initiate a P-II study assessing selgantolimod + VIR-2218 in treatment-experienced and treatment-naïve people living with HBV. People in the trial […]
Shots: The companies signed an agreement with to evaluate VIR-7832 vs PBO in P-Ib/IIa AGILE study in patients with mild to mod. COVID-19. The trial […]
Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study The […]
Shots: Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & […]
Shots: Daiichi Sankyo to conduct two-part P-I study assessing U3-1402+ Tagrisso as both a 1L and 2L dual regimen in patients with advanced or mNSCLC […]
Shots: The companies plan to conduct a P-II pilot study of tumor treating fields concomitant with Keytryda for 1L treatment of intrathoracic advanced/ metastatic PD-L1+ […]
Copyright © 2024 | WordPress Theme by MH Themes